Vaccines
EMA Begins Review of Pfizer and Valneva’s Lyme Disease Vaccine, a Potential First
European regulators have validated the marketing application for a six-valent Lyme vaccine that showed more than 70% efficacy in a 9,437-person Phase 3 trial. No human Lyme vaccine is currently approved.